PCYT1B

Across TCGA pan-cancer cohorts, PCYT1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCYT1B data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCYT1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCYT1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, ACC, and LIHC are the cancer types where PCYT1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	24	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LIHC	OS	Median	All	0.060	0.779	<.001	15	view →
TGCT	DFS	Median	All	0.066	0.802	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.331	0.596	.031	2	view →
UCEC	DFS	Median	II,III,IV	0.853	0.306	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCYT1B–LUAD (OS)

Open the LUAD breakdown →